The Depo-Provera settlement is a June 2026 "agreement in principle" that would resolve federal lawsuits alleging Pfizer failed to warn that its birth control shot raises the risk of meningioma, a usually-benign tumor of the brain and spinal-cord lining. But no recovery amount, claim form, or payout tier exists yet, so injured patients cannot currently be told what they will receive.
Depo-Provera (medroxyprogesterone acetate, a 150 mg contraceptive injection) is at the center of roughly 5,800 consolidated federal claims. The honest answer to "what can injured patients recover" is: an undisclosed, unfinalized amount, and only for a specific group of claimants. This page explains who is covered, why the numbers are still blank, and what a reader can practically do now.
Official resources:
- Read the official guidance from Pharmaceutical Technology — Use this primary source to verify the official guidance.
- Read the original argument from Drugwatch — Use this page to read the original argument in context.
Table of Contents
- What the injury and lawsuits actually allege
- Why no recovery amount exists yet
- Who is included — and who is left out
- The legal risk that could still shrink recovery
- What an injured patient can do now
- Frequently Asked Questions
What the injury and lawsuits actually allege
The core claim is not that Depo-Provera is banned or recalled. It is that Pfizer failed to warn patients and doctors that prolonged use of the shot raises the risk of meningioma. According to Pharmaceutical Technology's reporting on the FDA label change, the FDA approved an updated Depo-Provera label in December 2025 warning of meningioma risk with use over one year.
That label update is a real regulatory event, not a product ban. Meningiomas are usually benign, but they can require brain or spinal surgery, which is the harm most plaintiffs point to. The strongest supporting evidence is a French national study. As published in the BMJ in 2024, prolonged medroxyprogesterone-acetate use was associated with meningioma requiring surgery, with an odds ratio of 5.55.
Why no recovery amount exists yet
A settlement "in principle" is an outline, not a signed deal. A June 15, 2026 order summarized by Verus LLC confirms a global settlement in principle, but the terms are undisclosed and unfinalized. There is no approved claim form, no tier chart, and no published per-person recovery figure. Anyone quoting you a specific Depo-Provera payout right now is guessing.
The cases are consolidated in federal multidistrict litigation, MDL No. 3140, before Judge M. Casey Rodgers in the Northern District of Florida. Per Drugwatch's litigation timeline, the MDL held about 5,800 consolidated cases by mid-2026.
Who is included — and who is left out
The in-principle deal is narrow. It covers eligible claims already pending in the federal MDL, and it does not resolve every case.
According to MDL Update's tracker for MDL 3140, the agreement does not cover state-court cases, which are concentrated mostly in New York and Delaware. If your case sits in state court, this particular settlement framework may not reach you.
- Likely covered: claims filed and pending in federal MDL No. 3140
- Not covered by this deal: state-court cases in New York, Delaware, and elsewhere
- Not resolved: claims outside the "eligible" pool, even within the MDL
The legal risk that could still shrink recovery
Two unresolved legal fights could reduce or block payouts. The first is causation itself. The Daubert general-causation hearing — the step where a court decides whether the science is strong enough to link the drug to the injury in court — was reset to July 27, 2026, according to Drugwatch's timeline. Until a court rules, causation remains legally unadjudicated.
The second risk is preemption. Pfizer notes that the FDA rejected a proposed meningioma warning in 2024 before approving one in December 2025. That sequence, also documented in Drugwatch's timeline, supports a defense argument that Pfizer could not have added the warning earlier — which, if accepted, could defeat claims. There is also a scientific caveat worth knowing. The same BMJ study that found the elevated risk reported only 9 exposed cases out of 18,061 surgical cases, and the authors stress that overall meningioma risk stays low.
What an injured patient can do now
You cannot claim a settlement amount today, but you can preserve your position and stay informed. Warning signs of meningioma that warrant prompt medical attention include persistent headaches, vision changes, hearing loss, or seizures. A medical evaluation matters independently of any lawsuit.
- Gather records showing Depo-Provera use, especially duration over one year, plus any meningioma diagnosis or surgery.
- Note whether your potential case would fall in federal or state court, since the current deal covers only federal MDL claims.
- Watch the causation and preemption rulings, which will shape whether recovery happens at all.
- Track the official docket rather than marketing pages, using the JPML MDL 3140 court records for the Northern District of Florida.
Frequently Asked Questions
Has Depo-Provera been recalled?
No. The December 2025 FDA action was a label update warning of meningioma risk with use over one year, not a recall or ban.
Can I get a specific settlement amount right now?
No. The June 2026 deal is an agreement in principle with undisclosed, unfinalized terms and no claim form or payout tiers.
What if my case is in state court?
The current settlement covers only eligible federal MDL claims; state-court cases in New York, Delaware, and elsewhere are not included.